<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646058</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-N/2017/FJ-01</org_study_id>
    <nct_id>NCT03646058</nct_id>
  </id_info>
  <brief_title>Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode</brief_title>
  <acronym>BUPRIS</acronym>
  <official_title>Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at investigating if adjunctive buprenorphine at low dose to treatment as&#xD;
      usual is effective in reducing severe suicidal ideas in major depressive episode, and at&#xD;
      determining the most effective dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to two doses of buprenorphine (0.4mg and 0.8mg) or placebo.&#xD;
      The duration of treatment will be 21 days with 7 days withdrawal period. Two follow-up phone&#xD;
      calls at 3 and 6 months will investigate occurence of suicidal behavior.&#xD;
&#xD;
      The main outcome will be changes in suicidal ideas levels during the first week.&#xD;
&#xD;
      Secondary outcomes will be changes in suicidal ideas during the following 21 days, changes in&#xD;
      depression and psychological pain levels over the first 28 days, dropout rates, reasons and&#xD;
      occurence of side effects over the first 28 days, withdrawal symptoms dung the withdrawal&#xD;
      period, changes in neuropsychological and neuroimaging measures between Day 0 and Day 28.&#xD;
&#xD;
      Blood and stool samples will be collected at 4 time points and stored in a biobank for future&#xD;
      analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Beck Scale for Suicidal Ideation (SSI) scores from Day 0 to 7</measure>
    <time_frame>7 days</time_frame>
    <description>Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted), higher scores mean more intense suicidal ideas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Beck Scale for Suicidal Ideation (SSI) scores</measure>
    <time_frame>Day 8 to day 28</time_frame>
    <description>Clinician-based questionnaire measuring level of suicidal ideas over the last 7 days; 21 items scored 0 to 2; total score ranges from 0 to 38 (last 2 items not counted); higher scores mean more intense suicidal ideas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Beck Depression Inventory II (BDI-II) scores from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
    <description>Self questionnaire measuring depression level over the last 7 days; 13 items scored 0 to 3, with the total score ranging from 0 to 39; higher scores mean higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Montgomery-Asberg Depression Rating Scale (MADRS) from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
    <description>Clinician-based questionnaire measuring the level of depression of the last 7 days; 10 items score 0 to 6, with the total scores ranging fron 0 to 60; Higher scores mean higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Physical and Psychological Pain - Visual Analog Scale (PPP-VAS) scores from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
    <description>Visual Analog Scale measuring physical then psychological pain over 3 periods each (current, worst over the last 7 days, mean over the last 7 days); 6 dimensions in total; each dimension is scored from 0 (no pain) to 10 (maximal pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for discontinuing treatment over the first 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Patient's self-report; measurement will be the overall (over 28 days) incidence for each event reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects over the first 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Patient's self-report; measurement will be the overall (over 28 days) incidence for each event reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal symptoms</measure>
    <time_frame>Day 22 to day 28</time_frame>
    <description>Patient's self-report; measurement will be the incidence of any withdrawal symptom during the withdrawal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of a suicide attempt during the whole study</measure>
    <time_frame>180 days</time_frame>
    <description>Interview based; measurement will be the incidence of any suicide attempt between Day 0 and 28, between Day 29 and 90, and between Day 90 and 180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Iowa Gambling Task (IGT) scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Computerized test measuring decision-making; scores are the difference between advantageous and disadvantageous choices; scores range from -100 to + 100, higher scores means better performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in modified Stroop test scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical Stroop test modified with suicide-related words to measure specific attention bias; scores are the number of errors and total reaction time; higher scores mean worse performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in verbal fluency test scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test measuring verbal fluency skills for semantic and phonological categories; Patients are instructed to give as many words as possible for a given category then for words starting with a given letter, within a 1 minute time frame; Scores are the number of correct words; higher scores mean higher performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in N-Back test scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test of working memory using letters; scores are the number of words correctly identified for each level of recall (0 to 2 back); higher scores mean better performance; also, the number of omission and commission errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Go/No-Go test between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test of cognitive inhibition, letter version; scores are the number of omission and commission errors (higher scores mean worse performance) and reaction times (higher scores mean better performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Trail Making Test (TMT) scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Classical test of planning abilities; scores are the difference between the time to complete parts B and A of the test; Higher scores mean worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Implicit Association Test (IAT) scores between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>IAT version adapted for suicide/death; scores are the measure of reaction times in the association between suicide/death words and me/myself words; lower scores mean higher association.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) T1 measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain structural MRI-T1 sequence measured at Day 0 and Day 28 (5 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) T2 measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain structural MRI-T2 sequence measured at Day 0 and Day 28 (5 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) Diffusion Tensor Imaging (DTI) measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain Diffusion Tensor Imaging (DTI) sequence measured at Day 0 and Day 28 (20 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Magnetic Resonance Imaging (MRI) Resting State (RS) measures between Day 0 and 28</measure>
    <time_frame>28 days</time_frame>
    <description>Brain functional Resting State (RS) sequence measured at Day 0 and Day 28 (15 minutes)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Major Depressive Episode</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo pills sublingual during 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4mg buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8mg buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine, 0.4mg pills, sublingual</description>
    <arm_group_label>0.4mg buprenorphine</arm_group_label>
    <arm_group_label>0.8mg buprenorphine</arm_group_label>
    <other_name>Temgesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills, sublingual, specifically made to mimick buprenorphine pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has been correctly informed.&#xD;
&#xD;
          -  The patient must have given his/her informed and signed the consent form.&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan.&#xD;
&#xD;
          -  The patient is at least 18 years old and 65 years old at the most.&#xD;
&#xD;
          -  The patient is hospitalized or followed in consultation.&#xD;
&#xD;
          -  The patient has a current major depressive episode without psychotic features&#xD;
             according to the criteria of the &quot;Diagnostic and Statistical Manual of Mental&#xD;
             Disorders&quot;&#xD;
&#xD;
          -  The patient has a score &gt; 20 of the &quot;Montgomery-Asberg Depression Rating Scale&quot;.&#xD;
&#xD;
          -  The patient has a current Scale for Suicidal Ideation (SSI) score &gt; 8.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is participating in another interventional trial;&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study;&#xD;
&#xD;
          -  The patient is under judicial protection, or is an adult under guardianship;&#xD;
&#xD;
          -  The patient is under compulsory admission;&#xD;
&#xD;
          -  The patient refuses to sign the consent;&#xD;
&#xD;
          -  it is impossible to correctly inform the patient.&#xD;
&#xD;
          -  The patient is pregnant or breastfeeding.&#xD;
&#xD;
          -  The patient suffers from schizophrenia;&#xD;
&#xD;
          -  The patient has a lifetime history of substance use disorder (except tobacco and&#xD;
             caffeine), moderate to severe, according to criteria of the &quot;Diagnostic and&#xD;
             Statistical Manual of Mental Disorders&quot;;&#xD;
&#xD;
          -  The patient currently suffers from severe and/or unstable medical condition (including&#xD;
             severe respiratory or hepatic insufficiency) or a painful medical condition;&#xD;
&#xD;
          -  The patient has a current known sleep apnea.&#xD;
&#xD;
          -  The patient currently takes analgesic treatment (including Nonsteroidal&#xD;
             anti-inflammatory drug and paracetamol);&#xD;
&#xD;
          -  The patient currently takes central nervous depressant drugs at sedative doses (based&#xD;
             on the investigator's assessment), including benzodiazepines, antihistamines, and&#xD;
             sedative antipsychotics;&#xD;
&#xD;
          -  The patient currently takes major CYP3A4 Inhibitors and inducers;&#xD;
&#xD;
          -  The patient currently takes has received Electroconvulsivotherapy over the last 3&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Jollant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Sainte-Anne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Jollant, MD</last_name>
    <phone>+33(0)1 45 65 85 72</phone>
    <email>fabrice.jollant@parisdescartes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Hôpital Saint-Jacques</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Haffen, MD</last_name>
      <phone>+33(0)3 81 21 81 54</phone>
      <email>emmanuel.haffen@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Djamila Bennabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mircea Polosan, MD</last_name>
      <phone>+33(0)4 76 76 87 10</phone>
      <email>MPolosan@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Corruble, MD</last_name>
      <phone>+33(0)1 45 21 25 24</phone>
      <email>emmanuelle.corruble@bct.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Poulet, MD</last_name>
      <phone>+33(0)4 72 11 00 09</phone>
      <email>emmanuel.poulet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Brevet-Aeby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémence Bied, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine Ragonnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Courtet, MD</last_name>
      <phone>+33(0)4 67 33 85 81</phone>
      <email>p-courtet@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie Olié, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAPPA Jacques PREVERT</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Sauvaget, MD</last_name>
      <phone>+33(0)2.40.08.47.95</phone>
      <email>anne.sauvaget@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Les Sophoras</name>
      <address>
        <city>Nîmes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Torres, MD</last_name>
      <phone>+33(0)4 66 62 79 00</phone>
      <email>stmx@free.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume Collin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mocrane Abbar, MD</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>m-abbar@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jorge Lopez Castroman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ismaël Conegero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice Jollant, MD</last_name>
      <phone>+33 (0)1 45 55 65 92</phone>
      <email>fabrice.jollant@parisdescartes.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Pineau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann Mongin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Gorwood, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nemat Jaafari, MD</last_name>
      <phone>+33(0)5 16 52 61 18</phone>
      <email>nemat.jaafari@ch-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wissam El-Hage, MD</last_name>
      <phone>+33(0)2 47 47 80 43</phone>
      <email>wissam.elhage@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Lemaire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Suicidal ideas</keyword>
  <keyword>Depression</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Opioid agonist</keyword>
  <keyword>Mental pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicidal Ideation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

